JP2017530372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530372A5 JP2017530372A5 JP2017533704A JP2017533704A JP2017530372A5 JP 2017530372 A5 JP2017530372 A5 JP 2017530372A5 JP 2017533704 A JP2017533704 A JP 2017533704A JP 2017533704 A JP2017533704 A JP 2017533704A JP 2017530372 A5 JP2017530372 A5 JP 2017530372A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- pharmaceutical composition
- patient
- domain
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 15
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 15
- 230000003042 antagnostic Effects 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- WNMJYKCGWZFFKR-UHFFFAOYSA-N Alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 7
- 101710030892 FLT1 Proteins 0.000 claims 4
- 102100006565 FLT1 Human genes 0.000 claims 4
- 102100013180 KDR Human genes 0.000 claims 4
- 101710030888 KDR Proteins 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 102000018358 Immunoglobulins Human genes 0.000 claims 2
- 108060003951 Immunoglobulins Proteins 0.000 claims 2
- 108091007928 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 108091006028 chimera Proteins 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 229960002760 ziv-aflibercept Drugs 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N FOLFIRI regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 230000000973 chemotherapeutic Effects 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
Claims (14)
- 転移性結腸直腸癌（ｍＣＲＣ）を処置するための方法で使用するためのＶＥＧＦアンタゴニストを含む医薬組成物であって、該方法はＶＥＧＦアンタゴニストを患者に投与することを含み、ここで患者は、ｍＣＲＣと診断されており、かつＶＥＧＦ−Ａの上昇した発現を示すことに基づいてＶＥＧＦアンタゴニストを用いた処置に選択されており；ここで、ＶＥＧＦ−Ａの上昇した発現は、ｍＣＲＣを有する被験体におけるＶＥＧＦ−Ａのより低いレベルとの比較に基づいて決定される、上記医薬組成物。
- ＶＥＧＦアンタゴニストが、抗ＶＥＧＦ抗体、及び抗ＶＥＧＦ受容体抗体からなる群より選択される分子を含む、請求項１に記載の医薬組成物。
- ＶＥＧＦアンタゴニストがＶＥＧＦ受容体ベースのキメラ分子（ＶＥＧＦ Ｔｒａｐ）を含む、請求項１に記載の医薬組成物。
- ＶＥＧＦ Ｔｒａｐが、ＶＥＧＦＲ１の１つ又はそれ以上の免疫グロブリン（Ｉｇ）様ドメイン、ＶＥＧＦＲ２の１つ又はそれ以上のＩｇ様ドメイン、及び多量体化ドメインを含む、請求項３に記載の医薬組成物。
- ＶＥＧＦ Ｔｒａｐが、ＶＥＧＦＲ１のＩｇ様ドメイン２、ＶＥＧＦＲ２のＩｇ様ドメイン３、及び多量体化ドメインを含む、請求項４に記載の医薬組成物。
- ＶＥＧＦ Ｔｒａｐがｚｉｖ−アフリベルセプトである、請求項５に記載の医薬組成物。
- 該方法がイリノテカン、５−フルオロウラシル、及びロイコボリン（ＦＯＬＦＩＲＩ）を含む化学療法レジメンを被験体に施すことをさらに含む、請求項１〜６のいずれか１項に記載の医薬組成物。
- 抗ＶＥＧＦ療法に対して良好に応答する可能性がある転移性結腸直腸癌（ｍＣＲＣ）患
者を同定するためのインビトロの方法であって、該方法は、患者からのサンプルを提供すること、及びサンプルにおいてＶＥＧＦ−Ａのレベルを測定することを含み；ここで、ｍＣＲＣを有する被験体におけるＶＥＧＦ−Ａのより低いレベルの発現と比較してＶＥＧＦ−Ａの上昇したレベルの発現は、該患者を、抗ＶＥＧＦ療法に対して良好に応答する可能性がある患者として同定する、上記インビトロの方法。 - 抗ＶＥＧＦ療法は、ＶＥＧＦアンタゴニストの患者への投与を含み、ここでＶＥＧＦアンタゴニストは、抗ＶＥＧＦ抗体、及び抗ＶＥＧＦ受容体抗体からなる群より選択される分子を含む、請求項８に記載のインビトロの方法。
- 抗ＶＥＧＦ療法は、患者へのＶＥＧＦアンタゴニストの投与を含み、ここでＶＥＧＦアンタゴニストは、ＶＥＧＦ受容体ベースのキメラ分子（ＶＥＧＦ Ｔｒａｐ）を含む、請求項８に記載のインビトロの方法。
- ＶＥＧＦ Ｔｒａｐが、ＶＥＧＦＲ１の１つ又はそれ以上の免疫グロブリン（Ｉｇ）様ドメイン、ＶＥＧＦＲ２の１つ又はそれ以上のＩｇ様ドメイン、及び多量体化ドメインを含む、請求項１０に記載のインビトロの方法。
- ＶＥＧＦ Ｔｒａｐが、ＶＥＧＦＲ１のＩｇ様ドメイン２、ＶＥＧＦＲ２のＩｇ様ドメイン３、及び多量体化ドメインを含む、請求項１１に記載のインビトロの方法。
- ＶＥＧＦ Ｔｒａｐがｚｉｖ−アフリベルセプトである、請求項１２に記載のインビトロの方法。
- ＶＥＧＦ−Ａの発現レベルがＥＬＩＳＡを使用して測定される、請求項８〜１３のいずれか１項に記載のインビトロの方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051091P | 2014-09-16 | 2014-09-16 | |
| US62/051,091 | 2014-09-16 | ||
| US201562099630P | 2015-01-05 | 2015-01-05 | |
| US62/099,630 | 2015-01-05 | ||
| PCT/US2015/049279 WO2016044041A1 (en) | 2014-09-16 | 2015-09-10 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530372A JP2017530372A (ja) | 2017-10-12 |
| JP2017530372A5 true JP2017530372A5 (ja) | 2018-10-11 |
| JP6692358B2 JP6692358B2 (ja) | 2020-05-13 |
Family
ID=54207741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533704A Active JP6692358B2 (ja) | 2014-09-16 | 2015-09-10 | 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10525104B2 (ja) |
| EP (1) | EP3194974B1 (ja) |
| JP (1) | JP6692358B2 (ja) |
| KR (1) | KR102471057B1 (ja) |
| CN (1) | CN107076749B (ja) |
| AU (1) | AU2015318207B2 (ja) |
| CA (1) | CA2960890A1 (ja) |
| EA (1) | EA036671B1 (ja) |
| IL (1) | IL250905B (ja) |
| MX (1) | MX2017003387A (ja) |
| WO (1) | WO2016044041A1 (ja) |
| ZA (1) | ZA201701664B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110289092A (zh) | 2013-03-14 | 2019-09-27 | 奥特拉西斯公司 | 使用所测分析物改进疾病诊断的方法 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| RU2018127709A (ru) | 2016-01-22 | 2020-02-25 | Отрэйсис, Инк. | Системы и способы улучшения диагностики заболеваний |
| KR20190131538A (ko) * | 2017-03-31 | 2019-11-26 | 가부시키가이샤 히로츠 바이오 사이언스 | 암 환자의 치료 효과의 예측 및/또는 재발 모니터링 |
| CA3089481A1 (en) | 2018-01-26 | 2019-08-01 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| WO2020165483A1 (es) * | 2019-02-15 | 2020-08-20 | Universidad de Córdoba | Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos |
| CN114730612A (zh) * | 2019-07-13 | 2022-07-08 | 欧特雷瑟斯有限公司 | 使用肿瘤微环境活性蛋白质提高各种疾病的诊断 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20220390456A1 (en) * | 2019-10-17 | 2022-12-08 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
| AU2020393842A1 (en) | 2019-11-25 | 2022-06-16 | The Regents Of The University Of California | Long-acting VEGF inhibitors for intraocular neovascularization |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| CN101283280A (zh) * | 2005-08-18 | 2008-10-08 | Zadec私人有限公司 | 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途 |
| IN2012DN02046A (ja) * | 2009-08-14 | 2015-08-21 | Allergan Inc | |
| CA2891047A1 (en) | 2010-01-19 | 2011-07-18 | F. Hoffmann-La Roche Ag | Tumor tissue based biomarkers for bevacizumab combination therapies |
| CA2805709A1 (en) * | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
-
2015
- 2015-09-10 WO PCT/US2015/049279 patent/WO2016044041A1/en active Application Filing
- 2015-09-10 KR KR1020177007326A patent/KR102471057B1/ko active IP Right Grant
- 2015-09-10 EA EA201790549A patent/EA036671B1/ru unknown
- 2015-09-10 EP EP15771819.8A patent/EP3194974B1/en active Active
- 2015-09-10 AU AU2015318207A patent/AU2015318207B2/en active Active
- 2015-09-10 CN CN201580049558.1A patent/CN107076749B/zh active Active
- 2015-09-10 US US15/509,461 patent/US10525104B2/en active Active
- 2015-09-10 MX MX2017003387A patent/MX2017003387A/es unknown
- 2015-09-10 JP JP2017533704A patent/JP6692358B2/ja active Active
- 2015-09-10 CA CA2960890A patent/CA2960890A1/en active Pending
-
2017
- 2017-03-02 IL IL250905A patent/IL250905B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01664A patent/ZA201701664B/en unknown
-
2019
- 2019-11-21 US US16/690,459 patent/US11439683B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530372A5 (ja) | ||
| Touat et al. | Glioblastoma targeted therapy: updated approaches from recent biological insights | |
| Pestana et al. | Histology-agnostic drug development—considering issues beyond the tissue | |
| Lazăr et al. | New advances in targeted gastric cancer treatment | |
| Lurje et al. | EGFR signaling and drug discovery | |
| Chuma et al. | New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions | |
| Seeber et al. | Targeted therapy of colorectal cancer | |
| Greenall et al. | EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| Arrillaga-Romany et al. | Current status of antiangiogenic therapies for glioblastomas | |
| Becker et al. | Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy | |
| JP2017506506A5 (ja) | ||
| HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
| Wang et al. | New strategies in esophageal carcinoma: translational insights from signaling pathways and immune checkpoints | |
| JP2016527221A5 (ja) | ||
| Wadhwa et al. | Ramucirumab: a novel antiangiogenic agent | |
| Farghaly et al. | An updated patent review of VEGFR-2 inhibitors (2017-present) | |
| JP2015525230A5 (ja) | ||
| JP2017501137A5 (ja) | ||
| JP2017503481A5 (ja) | ||
| JP2015506961A5 (ja) | ||
| Pirker et al. | Alectinib in RET-rearranged non-small cell lung cancer—Another progress in precision medicine? | |
| Raimondi et al. | Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies | |
| Yu et al. | Targeted therapy for advanced or metastatic cholangiocarcinoma: focus on the clinical potential of infigratinib | |
| Stoffel | Targeted therapies for solid tumors: current status and future perspectives |